Current Prognostic Factors of Tetanus in Abidjan: 2005-2014

Yıl 2017, , 125 - 131, 15.09.2017

Aristophane Koffi Tanon Adama Doumbia Patrick Ahuatchi Coffie

https://doi.org/10.5799/jmid.367529

Cited By: 3

Öz

Objective:
To describe the epidemiological, clinical and prognosis aspects of tetanus in
patients hospitalized at the Infectious and Tropical Diseases Unit of
Treichville Teaching Hospital.

Methods:
A retrospective study of the medical records of all patients hospitalized
between 2005 and 2014. The “Dakar prognosis score” was established on the basis
of six parameters: incubation period, duration of invasion, site of entry,
presence of paroxysms, body temperature and pulse rate. A logistic regression
model was used to identify the factors associated with death.

Results:
Overall, 455 cases of tetanus were included, with a predominance of males
(86%). Most patients lived in Abidjan (77%). A very high proportion of cases
were generalized tetanus (96%), and 137 patients (30%) died. The factors
associated with death were age >60 years (aOR 2.76; 95% CI 1.07 to 9.91),
being a labourer (aOR 2.83 95% CI 1.07-9.39), a severe Dakar prognostic score
(aOR 5.76; 95% CI 2.26-14.72), no intrathecal serotherapy (aOR = 15.6; 95% CI
5.40- 44.84), no penicillin-therapy (aOR 2.33; 95% CI 1.11-4.87) and the
presence of complications (aOR 8.53, 95% CI 4.83-15.09).

Conclusion: This study identifies a
number of factors for a poor prognosis among patients with tetanus admitted to
our hospital, indicating that measures to reduce morbidity and mortality due to
tetanus should be strengthened and prevention improved in resource limited
settings. The prognostic parameters in “the Dakar score” should therefore be
adapted to the current epidemiological and clinical contexts in Côte d’Ivoire. 

Anahtar Kelimeler

Prognosis factors, tetanus Côte d’Ivoire, West Africa

Kaynakça

• 1. Vachon F. IVème international congress on tetanus (Dakar 6-11; 1975), Report. Méd Mal Infect 1975; 5,6: 310-11. 1975. 2. UNICEF, WHO. Sustainably eliminating maternal and neonatal tetanus: strategic plan 2012-2015. Available from: www.who.int/immunization/diseases/MNTEStrategicPlan_F.pdf. 3. Dalal S, Samuelson J, Reed J, Yakubu A, Ncube B, Baggaley R. Tetanus disease and deaths in men reveal need for vaccination. Bull World Health Organ 2016; 94 (8):613-21. 4. Tanon AK, Eholie SP, Coulibaly-Dacoury C, et al. [Morbidity and mortality of tetanus in the infectious and tropical diseases department in Abidjan 1985 - 1998]. Bull Soc Pathol Exot 2004; 97(4):283-287. 5. Aba T, Kra O, Ehui E, et al. [Clinical and developmental aspects of care-related tetanus in the reference service of the teaching hospital of Abidjan]. Bull Soc Pathol Exot 2011; 104(1):38-41. 6.Dao S, Oumar AA, Maiga I, Diarra M, Bougoudogo F. [Tetanus in a hospital setting in Bamako, Mali]. Med Trop 2009; 69(5):485-487. 7. Kakou AR, Eholie S, Ehui E, et al. [Localized tetanus in Abidjan: clinical and prognostic features (1976-1997)]. Bull Soc Pathol Exot 2001; 94(4):308-311. 8. Minta DK, Traore AM, Soucko AK, et al. [Mortality and morbidity of tetanus in the infectious diseases department, Point G teaching hospital, in Bamako, Mali (2004-2009)]. Bull Soc Pathol Exot 2012; 105(1):58-63. 9. Soumare M, Seydi M, Ndour CT, Ndour JD, Diop BM. [Epidemiology, clinical features and prognosis of juvenile tetanus in Dakar, Senegal]. Bull Soc Pathol Exot 2005; 98(5):371-373. 10. Sow PS, Seydi M, Diop BM, et al. Facteurs pronostiques du tétanos néonatal à Dakar. Prognosis factors for neonatal tetanus in Dakar. Med Mal Infect 2003; 33 (3):150-154. 11. Scobie HM, Patel M, Martin D, et al. Tetanus Immunity Gaps in Children 5-14 Years and Men ≥15 Years of Age Revealed by Integrated Disease Serosurveillance in Kenya, Tanzania, and Mozambique. Am J Trop Med Hyg 2017; 96(2):415-420. 12. Seydi M, Soumare M, Gbangba-ngai E, et al. [Current aspects of pediatric and adult tetanus in Dakar]. Med Mal Infect. 2005; 35(1):28-32. 13. Yeboue-Kouame BY, Bonny JS, Ahimon E, et al. Étude épidémiologique du tétanos à Abidjan et incidences professionnelles. Archives des Maladies Professionnelles et de Médecine du Travail 1999; 60 (2):132–135. 14. Aba YT, Kra O, Tanoh AC, et al. [Surgical tetanus in Abidjan, Cote d'Ivoire]. Med Sante Trop 2012; 22(3):279-282. 15. Adonis-Koffy LY, Tanon-Ano Bla MJ, N'Guessan R, Eboua TK, Adjaffi Sokolo AE, Timite-Konan AM. [Generalized tetanus with otitic portal of entry after using intra-auricular traditional remedies in a 2 old child]. Bull Soc Pathol Exot 2008; 101(4):301-302. 16. Boumandouki P, Kounkou RY, Teke-Bagamboula JN, Ekouele Mbaki H, Ndinga E. [Intramuscular injections of quinine and tetanus at the Centre Hospitalier Universitaire of Brazzaville, Congo]. Bull Soc Pathol Exot 2008; 101(4):298-300. 17. Ehui E, Kra O, Ouattara I, et al. [Generalized tetanus complicating a traditional medicine applied for snakebite]. Bull Soc Pathol Exot 2007; 100(3):184-185. 18. Ndour CT, Soumaré M, Diop BM, Touré AK, Badiane S. Tetanus in obstetric gateway in Dakar: epidemiological and prognostic aspects about 21 cases observed in the clinic of infectious diseases of the Dakar Teaching Hospital. Med Mal Infect 2002; 32:399-396. 19. Soumare M, Seydi M, Dia NM, et al. [Post-circumcision tetanus in Dakar, Senegal]. Bull Soc Pathol Exot 2008; 101(1):54-57. 20. Ribereau-Gayon R: Tetanus treatment in east African rural area (RD Congo-Zaire). Evaluation of a therapeutic protocol over 21 cases. Med Afr Noire 2000; 47(3):131-138. 21. Hosoglu S, Ayaz C, Faruk Geyik M, Yagmur Y, Faruk Kokoglu O. A continuing problem of tetanus in the southeast of Turkey. Clin Microbiol Infect 1997; 3(6):690-692. 22. Gallais H. [The value of intrathecal administration of antitetanus serum and corticoids in the treatment of manifest tetanus]. Nouvelle Presse Med 1977; 6(18):1571. 23. Kabura L, Ilibagiza D, Menten J, Van den Ende J. Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or equine tetanus antitoxin in the treatment of tetanus: a meta-analysis. Trop Med Int health. 2006; 11(7):1075-1081. 24. Miranda-Filho Dde B, Ximenes RA, Barone AA, Vaz VL, Vieira AG, Albuquerque VM. Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route. BMJ 2004; 328(7440):615. 25. Wateba M, Diop S, Nichols S, et al. [Intrathecal therapy with 1 500 UI of antitetanic serum and 1.5 g of intravenous metronidazole: prognosis of tetanus in hospitalized patients in Togo]. Sante 2008;18(3):125-129.